Patents by Inventor Alan Peter Lewis

Alan Peter Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12122828
    Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: October 22, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Gerben Bouma, Edward Thomas Coulstock, David Dixon, Stephanie Hopley, Alan Peter Lewis, Jessica Lynn Neisen
  • Publication number: 20240025988
    Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
    Type: Application
    Filed: September 5, 2023
    Publication date: January 25, 2024
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Gerben BOUMA, Edward Thomas COULSTOCK, David DIXON, Stephanie HOPLEY, Alan Peter LEWIS, Jessica Lynn NEISEN
  • Publication number: 20230374151
    Abstract: The present invention relates to improved compositions and methods for treating diseases, such as cancers that express aberrantly glycosylated MUC1 proteins, by providing a cell immunotherapy, wherein the cell immunotherapy is an immunomodulatory cell expressing a chimeric antigen receptor (CAR) that binds aberrantly glycosylate MUC1 proteins. The invention further relates to polynucleotides, expression vectors, and immunomodulatory cells comprising the immunotherapy, as well as related methods.
    Type: Application
    Filed: March 24, 2021
    Publication date: November 23, 2023
    Inventors: Tejinder Kaur BHINDER, Nicole CHRIST, Sergey LEKOMTSEV, ALAN Peter LEWIS
  • Patent number: 11802150
    Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: October 31, 2023
    Assignee: GlaxoSmith Kline Intellectual Property Development Limited
    Inventors: Gerben Bouma, Edward Thomas Coulstock, David Dixon, Stephanie Hopley, Alan Peter Lewis, Jessica Lynn Neisen
  • Publication number: 20230295295
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: January 19, 2023
    Publication date: September 21, 2023
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • Publication number: 20230242642
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: January 11, 2023
    Publication date: August 3, 2023
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • Publication number: 20230137032
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: July 12, 2022
    Publication date: May 4, 2023
    Inventors: Paul ALGATE, Stephanie Jane CLEGG, Jennifer L. CRAIGEN, Paul Andrew HAMBLIN, Alan Peter LEWIS, Patrick MAYES, Radha Shah PARMAR, Trevor Anthony Kenneth WATTAM
  • Patent number: 11613571
    Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 28, 2023
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Chika Akinseye, Tejinder Bhinder, Li Cui, Steven Grant, Laura Hook, Alan Peter Lewis, Martin Anibal Orecchia
  • Patent number: 11566347
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 31, 2023
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Patent number: 11419945
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: August 23, 2022
    Assignee: GLAXO GROUP LIMITED
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Publication number: 20220169717
    Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
    Type: Application
    Filed: November 30, 2021
    Publication date: June 2, 2022
    Inventors: Gerben BOUMA, Edward Thomas Coulstock, David Dixon, Stephanie Hopley, Alan Peter Lewis, Jessica Lynn Neisen
  • Patent number: 11203632
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: December 21, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Publication number: 20210347902
    Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
    Type: Application
    Filed: June 14, 2021
    Publication date: November 11, 2021
    Inventors: Tejinder Kaur BHINDER, Chong DING, Xu FENG, Wenqing JIANG, Alan Peter LEWIS, Yingli MA, Guhan NAGAPPAN, Radha Shah PARMAR, Yangsheng QIU, Liuqing YANG, Qing ZHANG, Yanjiao ZHOU
  • Patent number: 11098312
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 24, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Robyn Alexandra Emmins, Gary Brian Finka, Michael Hoare, Alan Peter Lewis, William John Kenneth Lewis, Adam Daniel McInally, Mark Uden, Ioannis Voulgaris
  • Patent number: 11078287
    Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 3, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Tejinder Kaur Bhinder, Chong Ding, Xu Feng, Wenqing Jiang, Alan Peter Lewis, Yingli Ma, Guhan Nagappan, Radha Shah Parmar, Yangsheng Qiu, Liuqing Yang, Qing Zhang, Yanjiao Zhou
  • Publication number: 20210115128
    Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: May 21, 2019
    Publication date: April 22, 2021
    Inventors: Chika AKINSEYE, Tejinder BHINDER, Li CUI, Steven GRANT, Laura HOOK, Alan Peter LEWIS, Martin Anibal ORECCHIA
  • Publication number: 20210017293
    Abstract: The present invention relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g. fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains e.g. human immunoglobulin (antibody) single variable domains, and also single variable domains derived from non-human sources such as a llama or camel, e.g. a VHH including a Nanobody™ (described in e.g. WO 94/04678 and WO 95/04079 inter alia). The invention further relates to uses, formulations, compositions comprising such modified C terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these molecules.
    Type: Application
    Filed: September 8, 2020
    Publication date: January 21, 2021
    Inventors: Claire Ashman, Mary Birchler, Rudolf M.T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
  • Publication number: 20200339663
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: May 12, 2020
    Publication date: October 29, 2020
    Inventors: Valeriu DAMIAN, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Patent number: 10808040
    Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Mary Birchler, Rudolf M. T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
  • Publication number: 20200197529
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 25, 2020
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam